Core Viewpoint - The application of artificial intelligence (AI) in Shenzhen New Industry Biomedical Engineering Co., Ltd. has significantly enhanced efficiency and reduced costs in the in vitro diagnostic product sector, providing a competitive edge in the market [1][2]. Group 1: AI Efficiency and Cost Reduction - AI technology has improved data collection efficiency by 10 times and reduced data processing time by 70%, allowing for quicker analysis and decision-making [9]. - The SATLARS T8 system, developed by the company, has been installed in over 200 hospitals, with more than 50% being tertiary hospitals, significantly shortening sample turnaround times [3]. - The automated processing system can enhance detection efficiency by over 30% through AI-driven sample quality assessment and intelligent scheduling [8]. Group 2: Market Landscape and Opportunities - The in vitro diagnostic market in China is dominated by multinational companies, holding 71.2% of the immunodiagnostic market and 53.2% of the biochemical diagnostic market [2]. - The global in vitro diagnostic market is projected to reach $109.2 billion by 2024, with emerging markets like China and India experiencing rapid growth [2]. Group 3: R&D and Innovation - The company is leveraging AI to analyze vast amounts of experimental data, which aids in the development of new reagents and reduces the traditional trial-and-error approach [10]. - AI is expected to shorten the development cycle of new reagent process parameters by over 50%, enhancing the company's responsiveness to market demands [10]. - The company aims to build a proprietary research knowledge graph based on accumulated structured internal data, transforming AI from an efficiency enhancer to an innovation driver in product development [10]. Group 4: Financial Performance - In the first half of the year, the company achieved a revenue of 2.185 billion yuan and a net profit of 771 million yuan [10].